2013 Archived Content
Fourth Annual

Cancer Biologics

Approaches Changing the Treatment of Cancer


Day 1 | Day 2 | Day 3 

Thursday, February 14

7:00 am Breakfast Presentation (Sponsorship Opportunity Available) or Morning Coffee

8:00 - 9:40 Plenary Keynote Panel: Emerging Technologies & Industry Perspectives 

This session features a series of presentations on emerging and hot technologies in diagnostics, drug discovery & development, informatics, and oncology. Interactive Q&A discussion with the audience will be included. - Read more 

Sponsored by

Biocartis  Elsevier  Luminex  RemedyMD  Scientia Advisors   Singulex 

9:40 Refreshment Break in the Exhibit Hall with Poster Viewing


ADCs: Pre-Clinical and Clinical Progress 

10:40 Chairperson's Remarks

Alison Betts, Ph.D., Associate Research Fellow, Pharmacokinetics, Dynamics and Metabolism (PDM), Pfizer Worldwide Research & Development

10:45 Anti-Müllerian Inhibiting Substance Type II Receptor Antibodies for Ovarian Cancer Therapy

Gregory P. Adams, Ph.D., Co-Leader, Developmental Therapeutics Program, Fox Chase Cancer Center

Antibodies with agonistic activity have been difficult to develop. Our efforts at isolating anti-MISIIR antibodies by phage display and using homology modeling to rationally design antibodies capable of binding to the highly conserved ligand binding site will be presented.

11:15 Improvements to ADC Safety with Calicheamicin

Puja Sapra, Ph.D., Director, Oncology Research Unit, Pfizer, Inc.

The ADC modality and its components, essential aspects of tumor cell biology and their impact on pharmacology and safety of ADC's will be discussed, with particular focus on clinical dose fractionation studies conducted with two calicheamicin conjugates in the clinic.

11:45 Clinical Development of a Novel Auristatin E-Based Antibody Drug Conjugate against SLC44A4 in Resistant Prostate Cancer

Leonard M. Reyno, M.D., Senior Vice President & CMO, Agensys, Inc.

ASG-5ME is a fully human antibody against SLC44A4 (expressed in 95% of prostate tumors) conjugated to monomethyl auristatin E.Phase I study will be discussed including challenges defining proof of concept in light of evolving standards of care.

12:15 pm Luncheon Presentations (Sponsorship Opportunities Available) or Lunch on Your Own

1:15 Refreshment Break in the Exhibit Hall with Poster Viewing


New Targets and Measures to Reach Difficult Targets 

1:40 Chairperson's Remarks

Leonard M. Reyno, M.D., Senior Vice President & CMO, Agensys, Inc.

1:45 Predictive Drug Discovery for Novel Cancer Biologics

John Hunter, Ph.D., Vice President, Antibody Research & Development, Compugen, Inc.

Compugen has applied its Predictive Discovery platform to identify novel members of the B7/CD28 family for targeted antibody immunotherapy in cancer.Validation data for representative targets will be presented.

2:15 Function-Orientated Screening Strategies to Identify Novel and More Effective Cancer Therapeutics

Mary Haak-Frendscho, Ph.D., CEO, Igenica, Inc. 

I will highlight Igenica's two innovative technology platforms, sTAg (surface-tagged tumor antigen profiling) and iTAb (in vivo anti-tumor antibody screening) that collectively offer function-orientated strategies to identify novel tumor antigens and effective antibody-based therapeutic candidates.

2:45 Proteomics for Trans-Membrane Targets for ADCs

John Terrett, Ph.D., CSO, Oxford Biotherapeutics, Inc.

Proteins with high expression on cancer plasma membranes are identified directly by mass spectrometric analysis of membranes from clinical samples. Targetability, prevalence, antigen density, and appropriate ADC development can be determined from a comprehensive proteomics database built at OBT.

3:15 Preclinical Development of MGA271, an Fc-Enhanced Anti-B7-H3 Monoclonal Antibody with Potent Antitumor Activity

Claudia Fieger, Ph.D., Scientist, Protein Biochemistry, Macrogenics, Inc. 

3:45 Valentine's Day Celebration and Poster Competition Winner Announced in the Exhibit Hall (Last Chance to View Posters)


Immunotherapy Approaches 

4:30 Chairperson's Remarks

Gregory P. Adams, Ph.D., Co-Leader, Developmental Therapeutics Program, Fox Chase Cancer Center

4:35 Understanding the Role of B Cells in Ovarian Cancer and Implications for Targeted Therapy

Nathalie Scholler, M.D., Ph.D., Assistant Professor, Obstetrics and Gynaecology, Gyn University of Pennsylvania

Anti-tumor effector T cells are inhibited by the tumor microenvironment. Recent experimental evidence demonstrates that B cell responses can regulate T cell functions in cancer patients, thus potentially enabling translational research with existing B cell-modifying drugs.

5:05 Adoptive Therapy of Cancer with Genetically Modified T Cells

Renier J. Brentjens, M.D., Ph.D., Associate Attending Physician, Associate Member, Department of Medicine, Memorial Sloan-Kettering Cancer Center

Production and clinical application of tumor targeted CAR T cells will be presented.Potential obstacles as well as approaches to address these limitations, including the use of IL-12 secreting T cells, will be discussed.

5:35 Allovectin®: In vivo Studies and Potential Synergy with Other Advanced Melanoma Immunotherapeutics

John Doukas, Ph.D., Senior Director, Pre-Clinical Safety and Efficacy, Vical, Inc.

Allovectin® is an immunotherapeutic currently completing evaluation in a pivotal Phase 3 study for metastatic melanoma. This presentation will review its proposed mechanisms of action and potential synergy with other immunotherapies, drawing supporting data from preclinical and clinical studies.

6:05 Sponsored Presentations (Opportunities Available)

6:35 Close of Day

Day 1 | Day 2 | Day 3 

Japan-Flag Korea-Flag China-Simplified-Flag China-Traditional-Flag  

Premier Sponsors

Beckman Coulter Life Sciences 

Boston Healthcare



Charles River no tagline


Cofactor Genonics


Menarini Silicon Biosystems






View All Sponsors